Adaptimmune Therapeutics plc (ADAP) Social Stream



Adaptimmune Therapeutics plc (ADAP): $1.73

-0.01 (-0.57%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ADAP to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

ADAPTIMMUNE THERAPEUTICS PLC (ADAP) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering ADAPTIMMUNE THERAPEUTICS PLC.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2022-01-14 5 $17 $7 $10.333 $1.74 493.85%
2022-02-23 5 $9 $7 $7.666 $1.74 340.57%
2022-03-14 5 $9 $3 $6.333 $1.74 263.97%
2022-05-17 5 $9 $2 $6 $1.74 244.83%
2022-08-04 4 $9 $2 $6 $1.74 244.83%
2022-09-09 4 $10 $2 $6.333 $1.74 263.97%
2022-10-04 4 $10 $1.5 $4.5 $1.74 158.62%
2022-11-09 5 $10 $1.5 $5.625 $1.74 223.28%
2022-11-14 5 $10 $3 $6.25 $1.74 259.2%
2023-01-05 6 $10 $3 $6 $1.74 244.83%

The Trend in the Analyst Price Target


Over the past 51 weeks, ADAP's average price target has gone down $3.67.

ADAP reports an average of 214.09% for its upside potential over the past 48 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2022-02-23 5 9 7 7.666 2.67 187.12%
2022-03-14 5 9 3 6.333 1.82 247.97%
2022-09-09 4 10 2 6.333 1.92 229.84%
2022-09-09 3 10 2 6.000 1.92 212.5%
2023-01-05 6 10 3 6.666 2.04 226.76%

ADAP Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.67 4 0 2 0 0 6

The Trend in the Broker Recommendations


ADAP's average broker recommendation rating improved by 0.93 over the prior 52 weeks.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • ADAP has a greater average analyst price target than 82.99% of all US stocks.
  • ADAP has a lower variance in analysts' estimates than -1210.47% of all US stocks.
  • In terms of how ADAPTIMMUNE THERAPEUTICS PLC fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is greater than 1334.78% of that group.
  • In the context of Healthcare stocks, ADAPTIMMUNE THERAPEUTICS PLC's number of analysts covering the stock is greater than 444.7% of them.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to ADAPTIMMUNE THERAPEUTICS PLC are OTLK, TTNP, and BCDA.

Is ADAP a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6636 seconds.